UROV News and Press, Urovant Sciences Ltd.

Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session...

Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-...

Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA ® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urin...

Data from a dedicated ambulatory blood pressure study showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate Urovant Sciences, Inc., a wholly- owned subsidiary of S...

Declining SPAC IPOs could indicate the SPAC bubble may have run its course. Brookfield Asset Management agrees to acquire Brookfield Property Partners after increasing its bid by 10%. Aggregate deal value in a highly competitive M&A space approaches $600 billion in Q1 202...

Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI). ...

Sina Corporation moves ahead sharply. Cash merger arbitrage spreads continue to outperform the IQ ARB Merger Arbitrage ETF. Merger arbitrage cash spreads advance again replicating previous week's returns. For further details see: Merger Arbitrage Analysis And Spread Perf...

GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1 2021 Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Adm...

The FDA has approved Urovant Sciences' ([[UROV]] -0.03%) Gemtesa (vibegron) for the treatment of overactive bladder, according to a posting to the agency's website.Last month the company announced positive data from long term study evaluating vibegron that showed 61% of 143 vibegron...

WeissLaw LLP Reminds UROV, NAV, PNM, and MVC Shareholders About Its Ongoing Investigations NEW YORK , Dec. 9, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questi...